ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adcock, I.
Right arrow Articles by Barnes, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adcock, I.
Right arrow Articles by Barnes, P.
Eur Respir J 1996; 9: 160-168
Copyright © ERS Journals Ltd 1996


Original Articles

Interactions of glucocorticoids and beta 2-agonists

IM Adcock, DA Stevens, and PJ Barnes

Beta 2-adrenoreceptor agonists and glucocorticosteroids are the two most effective treatments for asthma and are often used in combination. Glucocorticoids mediate their anti-inflammatory effects through the action of activated glucocorticoid receptors (GRs). Many of the effects of GRs on the synthesis of cytokines and other inflammatory mediators are due to a direct interaction with other deoxyribonucleic acid (DNA)-binding proteins belonging to the basic leucine zipper (bZIP) group of transcription factors, such as activator protein-1 (AP-1) and nuclear factor-kappa B (NF-kappa B). Beta 2-agonists are potent bronchodilators at low doses and at high doses can activate gene transcription via a bZIP protein, cyclic adenosine monophosphate (cAMP) response element binding protein (CREB). Activated GRs and CREB can interact with each other within the nucleus to modulate both DNA-binding and gene transcription in either a positive or inhibitory manner, depending on cell type. In lung cells, high doses of beta 2-agonists reduce the ability of GR to bind DNA, a process which is mediated by CREB activation. Inhibition of GR DNA-binding by CREB raises the possibility that high-dose beta 2-agonists could have functional antiglucocorticoid activity and may be a basis for the reported increase in asthma morbidity and mortality in industrialized countries, which have increasing per capita beta 2-agonist use.


This article has been cited by other articles:


Home page
ChestHome page
S. E. Overbeek, P. G. Mulder, S. M. Baelemans, H. C. Hoogsteden, and J.-B. Prins
Formoterol Added to Low-Dose Budesonide Has No Additional Antiinflammatory Effect in Asthmatic Patients
Chest, September 1, 2005; 128(3): 1121 - 1127.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
P. J. Barnes and I. M. Adcock
How Do Corticosteroids Work in Asthma?
Ann Intern Med, September 2, 2003; 139(5_Part_1): 359 - 370.
[Full Text] [PDF]


Home page
Eur Respir JHome page
P.J. Barnes
Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids
Eur. Respir. J., January 1, 2002; 19(1): 182 - 191.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]


Home page
Eur Respir JHome page
O. Zetterstrom, R. Buhl, H. Mellem, M. Perpina, J. Hedman, S. O'Neill, and T. Ekstrom
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Eur. Respir. J., August 1, 2001; 18(2): 262 - 268.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. J. CALHOUN, K. L. HINTON, and J. J. KRATZENBERG
The Effect of Salmeterol on Markers of Airway Inflammation Following Segmental Allergen Challenge
Am. J. Respir. Crit. Care Med., March 15, 2001; 163(4): 881 - 886.
[Abstract] [Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. E. ALDRIDGE, R. J. HANCOX, D. ROBIN TAYLOR, J. O. COWAN, M. C. WINN, C. M. FRAMPTON, and G. IAN TOWN
Effects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma
Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1459 - 1464.
[Abstract] [Full Text]


Home page
ThoraxHome page
R J Hancox, J O Cowan, E M Flannery, G P Herbison, C R McLachlan, C S Wong, and D R Taylor
Randomised trial of an inhaled beta 2 agonist, inhaled corticosteroid and their combination in the treatment of asthma
Thorax, June 1, 1999; 54(6): 482 - 487.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.